Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
50.00
-0.42 (-0.83%)
At close: Oct 17, 2024, 4:00 PM
50.18
+0.18 (0.36%)
Pre-market: Oct 18, 2024, 4:19 AM EDT
Revolution Medicines Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for RVMD stock have an average target of 50.25, with a low estimate of 30 and a high estimate of 61. The average target predicts an increase of 0.50% from the current stock price of 50.00.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RVMD stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 5 | 5 |
| Buy | 6 | 6 | 7 | 7 | 7 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 13 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $61 | Strong Buy | Reiterates | $61 | +22.00% | Oct 7, 2024 |
| Barclays | Barclays | Buy Maintains $54 → $60 | Buy | Maintains | $54 → $60 | +20.00% | Sep 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $56 | Strong Buy | Reiterates | $56 | +12.00% | Aug 12, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $55 → $54 | Buy | Maintains | $55 → $54 | +8.00% | Aug 8, 2024 |
| Wedbush | Wedbush | Buy Reiterates $59 | Buy | Reiterates | $59 | +18.00% | Aug 8, 2024 |
Financial Forecast
Revenue This Year
1.53M
from 11.58M
Decreased by -86.79%
Revenue Next Year
3.06M
from 1.53M
Increased by 100.00%
EPS This Year
-3.52
from -3.86
EPS Next Year
-3.92
from -3.52
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 12.6M | 25.2M | 159.4M | ||
| Avg | 1.5M | 3.1M | 22.3M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 8.8% | 1,547.1% | 5,108.8% | ||
| Avg | -86.8% | 100.0% | 629.4% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.31 | -3.35 | -1.84 | ||
| Avg | -3.52 | -3.92 | -3.95 | ||
| Low | -4.20 | -4.17 | -4.46 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.